



# MEDIA RELEASE

**For immediate release**

Thursday 17 May 2021

## **U.S. NIH provides funding to the University of Michigan to acquire a 4DMedical pre-clinical scanner**

The U.S. National Institutes of Health (NIH) has funded the acquisition of a 4DMedical Permetium pre-clinical scanner by the Department of Radiology at the University of Michigan School of Medicine. The imaging system will be used to perform unprecedented quantitative imaging of lung function to assist investigators with obtaining exquisite multidimensional images of lung vascular changes to assess progression and interventions of many diverse disease indications.

The patented 4DMedical *XV Technology*<sup>TM</sup> suite will also provide investigators with the ability to evaluate cardiothoracic vascular re-modelling associated with interstitial lung disease including asthma, idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.

In its application for US\$600,000, the influential and respected University of Michigan investigators considered 4DMedical's Permetium<sup>TM</sup> product developed in Australia as "the only commercially available device for ultra-high-resolution imaging and quantification of cardiothoracic disease models."

The funding submission summarised the Permetium scanner as the optimal means to "...a safe, quick, and inexpensive tool that not only provides high-resolution images but also yields detailed, regional information on lung function. The 4D XV pre-clinical scanner is an indispensable necessity for the cardiothoracic translational research efforts which include evaluation of novel classes of drugs focused on treatment of cardiothoracic diseases."

The scanner is to be installed at the University of Michigan Center for Molecular Imaging, which is under the Directorship of Dr. Brian D. Ross, PhD, the Roger A. Berg Professor of Radiology, Associate Chair of Basic Science Research and Professor of Biological Chemistry where it will be integrated into the imaging shared resource and utilized by established NIH investigators. Professor Ross' team is developing applications for using imaging to assess disease status and positive impact of experimental treatment interventions in living tissue and states the 4D Medical scanner "...will change our science\*."

<more>

The University of Michigan Department of Radiology has a rich history of significant contributions in basic science and in medicine. Installation of this scanner will enable establishment of a Preclinical Lung and Heart Physiology Shared Laboratory within the Center to realise the potential of the 4DMedical Permetium to further our understanding of the biological underpinnings of disease initiation and progression and to advance novel therapeutic interventions.

<ends>

## **CONTACT**

Clint Rodgers; Vice President Marketing and Communications: +61 422378131 / +61 428587350  
(24 hours)

## **INTERVIEW**

Managing Director / Chief Executive Officer, Dr Andreas Fouras, is available for media interview.

## **IMAGERY**

Imagery downloadable at: <https://brandfolder.com/s/tksvzv4crb5mrqn7wtbxm4>

## **PRODUCT INFORMATION**

<https://4dmedical.com/our-products/preclinical/hardware/permetium/>

## **BACKGROUNDER**

4DMedical is a medical technology company transforming respiratory diagnostics for all lung disorders including coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

Through its technology 4DMedical is providing clinicians with greater insights into diseases of the lung, 4DMedical is focusing on providing better information to doctors and patients about lung function.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, assisting in providing sensitive, early diagnosis, and to monitor changes over time. The company's Software-as-a-Service (SaaS)-enabled scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower and safer levels of radiation than traditional methods.

Better information means better decisions, and better outcomes.

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical was founded in 2012 and is listed on the Australian Securities Exchange (ASX: 4DX).

**4dmedical.com**

Melbourne, Australia

Los Angeles, USA